Sign in
Taking people in United StatesEarly phase 1

Semaglutide with teplizumab for early-stage type 1 diabetes

Tests semaglutide against placebo in people with early type 1 diabetes receiving teplizumab.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Status
Recruiting
Phase
Early phase 1
People taking part
24 people, planned
Started
12 Jun 2024
Expected to end
Mar 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Semaglutide (Rybelsus®)
  • Placebo
Record updated
18 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12-50 with early-stage type 1 diabetes. It studies how a GLP-1Ra drug affects blood sugar and blood vessels, including in people getting teplizumab.

Age
12-50 years
Sex
All sexes
Disease stage
Stage 2 type 1 diabetes (at least 2 islet auto-antibodies plus raised blood sugar on a fasting or meal/glucose test), or early stage 3 type 1 diabetes diagnosed within 8 weeks of the first study visit.
Earlier treatment
Cannot take any diabetes medicine, systemic glucocorticoid, antipsychotic, immunosuppressant or antihypertensive, among other listed drugs. Antioxidant vitamin supplements not allowed in the 2 weeks before a study.
Biomarker or test result
At least 2 islet auto-antibodies (stage 2). For stage 3, HbA1c 6.5% (48 mmol/mol) to 8.0% (64 mmol/mol) at diagnosis, or HbA1c 5.7% (39 mmol/mol) to 6.4% (46 mmol/mol) with an oral glucose test meeting ADA criteria for stage 3 type 1 diabetes.

Main reasons for not taking part

  • Family history of medullary thyroid carcinoma
  • Pancreatitis or gastroparesis diagnosed in the past 3 years
  • Pregnancy, or peri- or post-menopausal women
  • Active smoker
  • Past diabetic ketoacidosis needing hospital admission (stage 3 group)

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Age: 12-50 years
  • BMI: 18-31 kg/m2 (adults) or 5-95th %ile (pediatric)
  • Stage 2 T1DM (i.e., ≥ 2 islet auto-antibodies and:
  • fasting glucose ≥ 100 mg/dL and < 126 mg/dL OR
  • 2-hr OGTT /MMTT ≥ 140 mg/dL and < 200 mg/dL OR
  • During an OGTT having a glucose of > 199 mg/dL at 30, 60, or 90 minutes)

Who cannot take part

  • Medications: Any diabetes medication, any antioxidant vitamin supplement (<2 weeks before a study), any systemic glucocorticoid, antipsychotic, atenolol, metoprolol, propranolol, niacin, any thiazide diuretic, any OCP with > 35 mcg ethinyl estradiol, growth hormone, any immunosuppressant, antihypertensive, any antihyperlipidemic
  • Medications: Any diabetes medication, any antioxidant vitamin supplement (<2 weeks before a study), any systemic glucocorticoid, antipsychotic, atenolol, metoprolol, propranolol, niacin, any thiazide diuretic, any OCP with > 35 mcg ethinyl estradiol, growth hormone, any immunosuppressant, antihypertensive, any antihyperlipidemic
  • Family history of medullary thyroid carcinoma
  • DKA history: history of diabetic ketoacidosis requiring hospital admission
  • Family history of medullary thyroid carcinoma
  • eGFR by MDRD equation of < 60 mL/min/1.73m2
  • AST or ALT > 2.5 times ULN
  • HbA1c 6.5% to 8.0% at diagnosis OR
  • HbA1c 5.7% to 6.4% with oral glucose test meeting ADA criteria for stage 3 T1DM within the past three months prior to or during screening visit
  • Age: 12-50 years
  • Comorbidities:
  • SBP > 140 mmHg and DBP > 100 mmHg
  • Diagnosis of pancreatitis or gastroparesis within the past 3 years
  • Other: pregnancy, peri- or post-menopausal women, active smoker; Aim 4: Early Stage 3 T1DM with GLP-1Ra Monotherapy Inclusion Criteria
  • BMI: 18-31 kg/m2 (adults) or 5-95th %ile (pediatric)
  • Early stage 3 T1DM with either
  • Time of stage 3 diagnosis: within eight weeks of first study visit
  • Comorbidities:
  • Diagnosis of pancreatitis or gastroparesis within the past 3 years
  • Other: pregnancy, peri- or post-menopausal women, active smoker

Other criteria

  • Aims 1-3: Stage 2 T1DM with TZIELD® and GLP-1Ra

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 50 years old?

Where in United States

  • Vanderbilt University Medical CenterNashville, United StatesContact: Daniel J Moore, MD, PhDTaking people

About the trial

What the trial wants to find out

The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The meal tests are followed by two post-treatment tests, one with the GLP-1Ra drug and the other with a placebo. Each test involves blood draws before and during the meal test, GLP-1Ra or placebo administration, and an ultrasound to measure blood vessel function. The goal is to see if GLP-1Ra can help manage blood sugar levels and improve cardiovascular health in this population.

The 4 groups in the trial

  • Participants receiving placebo, Stage 2 T1DM participantsPlacebo, for comparison

    Participants receive a placebo orally once before the pre-TZIELD® MMTT. Participants also receive a placebo orally once before one of the post-TZIELD® MMTTs.

    Treatment: Placebo

  • Participants receiving a semaglutide (Rybelsus®), Stage 2 T1DM participantsTreatment being tested

    Participants receive 7mg of semaglutide (Rybelsus®) orally once before one of the post-TZIELD® MMTTs. Rybelsus is only given one time.

    Treatment: Semaglutide (Rybelsus®)

  • Placebo Comparator: Participants receiving placebo, Stage 3 T1DM participantsPlacebo, for comparison

    Participants receive a placebo orally once before each MMTT.

    Treatment: Placebo

  • Experimental: Participants receiving a semaglutide (Rybelsus®), Stage 3 T1DM participantsTreatment being tested

    Participants receive 7mg of semaglutide (Rybelsus®) orally once before each MMTT.

    Treatment: Semaglutide (Rybelsus®)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab
Plain-language title
Semaglutide with teplizumab for early-stage type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06338553, who can take part
Record updated
18 December 2025